Climb Bio (CLYM) Expected to Announce Earnings on Thursday

Climb Bio (NASDAQ:CLYM) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Climb Bio to post earnings of ($0.15) per share for the quarter.

Climb Bio Price Performance

Shares of Climb Bio stock opened at $1.35 on Thursday. Climb Bio has a 1 year low of $1.20 and a 1 year high of $11.55. The stock has a market cap of $90.75 million, a P/E ratio of -0.63 and a beta of -0.19. The stock’s fifty day simple moving average is $1.64.

Analyst Ratings Changes

Several analysts recently commented on the stock. Leerink Partners assumed coverage on shares of Climb Bio in a research note on Monday, December 2nd. They issued an “outperform” rating and a $10.00 price objective for the company. Leerink Partnrs raised Climb Bio to a “strong-buy” rating in a research report on Monday, December 2nd.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.